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Background: Febrile neutropenia (FN) is common in breast cancer patients undergoing chemotherapy. Risk factors
for FN have been reported, but risk models that include genetic variability have yet to be described. This study
aimed to evaluate the predictive value of patient-related, chemotherapy-related, and genetic risk factors.
Methods: Data from consecutive breast cancer patients receiving chemotherapy with 4–6 cycles of fluorouracil,
epirubicin, and cyclophosphamide (FEC) or three cycles of FEC and docetaxel were retrospectively recorded.
Multivariable logistic regression was carried out to assess risk of FN during FEC chemotherapy cycles.
Results: Overall, 166 (16.7%) out of 994 patients developed FN. Significant risk factors for FN in any cycle and the
first cycle were lower platelet count (OR = 0.78 [0.65; 0.93]) and haemoglobin (OR = 0.81 [0.67; 0.98]) and homozygous
carriers of the rs4148350 variant T-allele (OR = 6.7 [1.04; 43.17]) in MRP1. Other significant factors for FN in any cycle were
higher alanine aminotransferase (OR = 1.02 [1.01; 1.03]), carriers of the rs246221 variant C-allele (OR = 2.0 [1.03; 3.86]) in
MRP1 and the rs351855 variant C-allele (OR = 2.48 [1.13; 5.44]) in FGFR4. Lower height (OR = 0.62 [0.41; 0.92])
increased risk of FN in the first cycle.
Conclusions: Both established clinical risk factors and genetic factors predicted FN in breast cancer patients.
Prediction was improved by adding genetic information but overall remained limited. Internal validity was
satisfactory. Further independent validation is required to confirm these findings.
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Chemotherapy-induced neutropenia (CIN) and febrile
neutropenia (FN) are serious and frequent complications
in breast cancer patients receiving adjuvant chemotherapy,
and they result in hospitalisations [1-3] and chemotherapy
dose reductions or delays that impact on treatment out-
come and short-term mortality [4]. Adjuvant fluorouracil,
epirubicin, and cyclophosphamide (FEC) chemotherapy
has an FN risk of between 9% and 14% (low-intermediate
risk) [5].
Antibacterial or antifungal prophylaxis has recently
been recommended for neutropenic patients expected to
have a prolonged low neutrophil count or with other risk
factors that favour complications [6]. Prophylaxis with
granulocyte colony-stimulating factor (GCSF) in patients
at high risk of FN (>20%) is recommended in international
guidelines [5,7,8]. For chemotherapy regimens with an
intermediate FN risk (10-20%), the European Organisation
for Research and Treatment of Cancer (EORTC) GCSF
guideline recommends that patient risk factors should also
be considered to determine individual risk of FN [5] and
the likely benefit of prophylactic GCSF. Therefore, it is
important to identify patients at high risk of FN before the
initiation of chemotherapy to provide them with appropri-
ate prophylactic measures.
Risk models for the occurrence of CIN [9] and FN [10]
in patients with breast cancer have been published. The
risk factors identified include older age, lower weight,
higher planned dose of chemotherapy, higher number of
planned chemotherapy cycles, vascular comorbidity, lower
baseline white blood cell count (WBC), lower platelet and
neutrophil count, and higher baseline bilirubin. Prior
chemotherapy, abnormal liver or renal function, low WBC,
higher chemotherapy intensity, and planned delivery were
identified as risk factors for neutropenic complications in
a prospective US study of patients with different types of
cancer [11]. Poor performance status and low lymphocyte
and neutrophil counts were risk factors in a European
study of solid tumour patients [12], as were tumour stage
and number of comorbidities in elderly patients with solid
tumours [13].
These risk models of CIN or FN that included patient-
or chemotherapy-related factors were reported to be pre-
dictive. However, more refined models are necessary to
achieve satisfactory performance in independent patient
populations that include existing and emerging types of
data, including stable genetic factors that are easily meas-
urable, objective, and potentially independent from the in-
herent viabilities of clinical decision-making. Several studies
have assessed the impact of genetic factors on haemato-
logical toxicity, but these studies were small in size or lim-
ited to only a few candidate genetic factors [14-16].
The objective of this study was to develop risk models for
the occurrence of FN in breast cancer patients receivingFEC chemotherapy in any cycle and the first cycle based
on a large set of patient-related, chemotherapy-related,
and genetic characteristics.
Methods
Study population
We retrospectively studied early (i.e., no distant metas-
tases; Stage I-IIIC) breast cancer patients treated be-
tween 2000 and 2010 at the Leuven Multidisciplinary
Breast Cancer Center of the University Hospitals Leuven,
Belgium. Consecutive patients were included if they re-
ceived either three cycles of neoadjuvant or adjuvant com-
bination chemotherapy consisting of FEC followed by
three cycles of docetaxel or four to six cycles of FEC.
Patient-related factors (genetics and tumour characteris-
tics) and chemotherapy-related factors were retrospectively
recorded in a clinical database. Haematological toxicities
included were: FN (defined as an absolute neutrophil
count (ANC) < 0.5 × 109/L and a body temperature ≥ 38°C
according to the Infectious Diseases Society of America),
prolonged grade 4 neutropenia (≥ 5 days), deep neutro-
penia (< 100/μl), grade 3/4 thrombocytopenia, and grade
3/4 anaemia during FEC chemotherapy cycles. Haemato-
logical toxicities that occurred during chemotherapy cycles
with docetaxel were not included in the model. Grade 3/4
non-haematological toxicities were also recorded (toxicity
grade based on the Common Terminology Criteria for Ad-
verse Events 3.0 [17]). During most of the study period,
only primary prevention with GCSF was reimbursed and,
therefore, only used in selected patients aged 65 or over.
Similarly, secondary use of GCSF was only reimbursed and
used if patients had FN in the previous cycle or if deep neu-
tropenia occurred for at least five days (although the latter
was not systematically measured during the study period).
The study design and full analysis of single nucleotide
polymorphisms (SNPs) have previously been described in
detail [18]; however, in the previous analysis the association
of SNPs with FN was only adjusted for age, growth factor
use, BMI, and planned cycles of chemotherapy. Only those
SNPs that have been reported to be associated with haem-
atological toxicity or to play a role in the metabolism of
FEC chemotherapy were included in the current study. Lo-
gistic regression was performed to describe the association
of SNPs with haematological toxicity, adjusted for known
predictors of FN risk such as age, growth factor use, and
planned number of cycles of chemotherapy. The ethics
committee of the University Hospitals Leuven approved the
study and all patients included in the study had given writ-
ten informed consent for collection of genetic samples and
for further analyses using this material and associated data.
Endpoints and predictor variables
The primary endpoint of the study was FN in any cycle,
and FN occurring in the first cycle (cycle 1) was the
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ered as predictors of FN: planned doses of fluorouracil,
epirubicin and cyclophosphamide (FC, 600 mg/m2 until
August 2004 and 500 mg/m2 after this date; epirubicin
100 mg/m2), age at diagnosis, height, weight, body mass
index (BMI), body surface area (BSA), chemotherapy set-
ting (i.e. adjuvant or neoadjuvant), use of GCSF (informa-
tion only available on primary or secondary use), planned
cycles of FEC chemotherapy, selected SNPs [18], baseline
WBC, ANC and platelet count, and other baseline labora-
tory parameters such as haemoglobin, bilirubin, alanine
aminotransferase (ALT), aspartate aminotransferase (AST)
and creatinine. Although timing and reasoning of GCSF
use were incomplete, its potential impact on the variables
included in the final model was assessed for exploratory
analysis.
Statistical analysis
All analyses were performed using Stata/SE version 12.1
(StataCorp LP, College Station, TX, USA). All statistical
tests were carried out two-sided at a 5% significance
level and 95% confidence intervals (CIs) were obtained.
Descriptive and univariable analysis
Binary and categorical data were summarised using fre-
quencies and percentages. Continuous data were reported
using means and standard deviations. In the univariable
analysis of SNPs, the impact of multiple testing was
assessed by separately calculating the false discovery
rate (FDR) for each endpoint [19]. Associations between
the endpoints and binary or categorical variables were
assessed using the chi-squared test or Fisher’s exact test,
as appropriate. Continuous variables and their associa-
tions with the endpoints were assessed using univariable
logistic regression analysis. Variables were further assessed
in multivariable logistic regression analysis if a trend was
seen in the univariable analysis (p ≤ 0.25), as recom-
mended [20]. Linear correlations between potential pre-
dictors were assessed by calculating Pearson’s correlation
coefficient and monotonic correlations were assessed
using Spearman’s rank correlation coefficient. Variables
were regarded as being dependent if the correlation coeffi-
cient was ≥ 0.7 or the correlation p-value was ≤ 0.05.
Multivariable analysis
Multivariable logistic regression analysis was used to as-
sess the joint explanatory value of the candidate variables
identified in univariable analysis; variables were included
in the final multivariable models if their corresponding
p-value was ≤ 0.05. Where simultaneous inclusion of
dependent variables led to estimation problems (collinearity
issues), the variable that explained more of the variability
present in the endpoint was finally used. As patient-related
and chemotherapy-related factors were already establishedas risk factors in several previous risk models, these var-
iables were entered into the model first, ordered accord-
ing to the p-value obtained in univariable analysis. SNPs
were subsequently added. Interactions between variables
were assessed. Model fit was assessed with the Hosmer-
Lemeshow [21] goodness-of-fit test. Test characteristics
such as specificity (proportion of negatives correctly iden-
tified as not having an event), sensitivity (proportion of
positives correctly identified as having an event), positive
predictive value (PPV, proportion of patients identified to
have an event who had an event) and negative predictive
value (NPV, proportion of patients identified not to have
an event who did not have an event) were obtained. The
predictive ability of the final models was assessed by cal-
culating the area under the receiver operating character-
istic (ROC; sensitivity over 1-specificity) curve.
To test the internal validity of the final models, non-
parametric bootstrapping was performed [22]. Bootstrap
estimates of the 95% CIs of the multivariable models were
obtained by resampling the data 200 times. The obtained
95% CI estimates of the bootstrap resampling were com-
pared to the 95% CIs calculated by the multivariable logis-
tic regression model.Results
Characteristics of the study group
Of 1,012 patients that received FEC chemotherapy be-
tween 2000 and 2010, 18 patients were excluded due to
receiving chemotherapy prior to FEC, which may have
impacted on FN risk. The majority of 994 eligible pa-
tients received adjuvant chemotherapy (n = 874, 88.0%);
the remainder received neoadjuvant chemotherapy. Most
patients received three cycles of combination chemother-
apy with FEC followed by three cycles of docetaxel (n =
507, 51.0%) or six cycles of FEC (n = 405, 40.7%) (Table 1).
The most common type of breast cancer was invasive
ductal carcinoma (n = 823, 82.8%) and patients mostly had
grade 2 (n = 334, 34.1%) or grade 3 (n = 606, 61.9%) tu-
mours. FN occurred in any cycle in 166 (16.7%) patients,
of which 107 (10.8%) had FN in the first cycle of FEC
chemotherapy. The most common haematological tox-
icity was prolonged grade 4 neutropenia (n = 345,
34.7%). Other haematological toxicities such as grade
3/4 thrombocytopenia and severe bleeding, and grade
3/4 non-haematological toxicities such as diarrhoea,
mucositis, and neuropathy were rare (n < 10, <1%). Pri-
mary prophylactic GCSF (before a CIN or FN event oc-
curred) was given to 15 (1.5%) patients and the majority
received no GCSF (n = 654, 65.8%). Additional toxicities
and other relevant characteristics such as planned number
of chemotherapy cycles, tumour stage, and subtype are
presented in Table 1. The list of SNPs included in the ana-
lyses is shown in Table 2.
Table 1 Characteristics of the study population, the
tumours, and the administered chemotherapy including
toxicities
Patient characteristics Mean ± standard
deviation or frequency (%)
Age at diagnosis (years) (n = 994) 50.4 ± 9.6
Body mass index (kg/m2) (n = 981) 24.9 ± 4.1
Body surface area (m2) (n = 993) 1.7 ± 0.1
Tumour characteristics
Tumor status 994 (100)
- Primary tumour 966 (97.2)
- Relapsed tumour 28 (2.8)
Tumour gradea 979 (98.5)
- 1 39 (4.0)
- 2 334 (34.1)
- 3 606 (61.9)
Tumour type 994 (100)
- Invasive ductal carcinoma 823 (82.8)
- Invasive lobular carcinoma 103 (10.4)
- Mixed 27 (2.7)
- Others 41 (4.1)
Tumour stageb 978 (98.4)
- I 113 (11.5)
- IIA 306 (31.3)
- IIB 245 (25.1)
- IIIA 193 (19.7)
- IIIB 44 (4.5)
- IIIC 77 (7.9)
Receptor status
- Estrogen receptor positive 683 (68.8)
- Progesterone receptor positive 577 (58.1)
- HER2 positive 205 (20.7)
Subtypec 981 (98.7)
- Luminal A 325 (33.1)
- Luminal B HER2- 234 (23.9)
- Luminal B HER2+ 121 (12.3)
- HER2-like 84 (8.6)
- Triple negative 217 (22.1)
Nottingham Prognostic Index (NPI)d (n= 757) 5.0 ± 0.9
Chemotherapy characteristics
Chemotherapy setting 994 (100)
- Adjuvant 874 (87.9)
- Neoadjuvant 120 (12.1)
Planned cycles of FEC chemotherapy 994 (100)
- 3 cycles FEC 559 (56.2)
- 4 or 5 cycles FEC 2 (0.2)
- 6 cycles FEC 433 (43.6)
Table 1 Characteristics of the study population, the
tumours, and the administered chemotherapy including
toxicities (Continued)
Relative dose intensity (RDI) (n = 994) 0.96 ± 0.1
Growth factor use 994 (100)
- Primary 15 (1.5)
- Secondary 325 (32.7)
- None 654 (65.8)
Baseline laboratory parameters
White blood cell count (109/L) (n = 985) 7.2 ± 2.0
Absolute neutrophil count (109/L) (n= 937) 4.4 ± 1.6
Haemoglobin (g/dl) (n = 989) 13.3 ± 1.0
Platelets (109/L) (n = 985) 275.4 ± 65.1
Total bilirubin (mg/dl) (n = 915) 0.4 ± 0.2
Creatinine (mg/dl) (n = 957) 0.8 ± 0.1
Alanine aminotransferase (U/L) (n = 955) 23.3 ± 15.3
Aspartate aminotransferase (U/L) (n = 955) 21.9 ± 11.1
FEC chemotherapy toxicities
Febrile neutropenia 166 (16.7)
- Febrile neutropenia in first cycle 107 (10.7)
Prolonged (≥ 5 days) grade 4 neutropenia 345 (34.7)
Deep neutropenia (< 100/μl) 93 (9.4)
Other grade 3–4 toxicities 46 (4.6)
FEC, fluorouracil, epirubicin and cyclophosphamide; HER2, human epidermal
growth factor receptor 2.
aAccording to the Ellis and Elston grading system [23].
bAccording to the TNM classification [24].
cAccording to Brouckaert et al. [25].
dAccording to Lee et al. [26].
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All candidate predictors (p ≤ 0.25) for FN in any cycle
and in cycle 1 are shown in Table 3. Patient-related factors
(genetics, laboratory parameters, etc.) and chemotherapy-
related factors fulfilled the inclusion criteria for the multi-
variable analysis. The number of planned FEC cycles,
WBC, ANC, platelet count, and haemoglobin were sig-
nificantly associated with FN in any cycle and cycle 1
(p ≤ 0.05). SNPs significantly associated with FN in any
cycle and cycle 1 were the rs4148350, rs45511401, and
rs246221 variants in MRP1 (multidrug resistance-
associated protein 1). The FDR for associated SNPs for
any cycle FN was 0.47 and 0.33 for cycle 1 FN. There
were no correlations between SNPs included in the
final model and patient-related or chemotherapy-related
factors.
Risk factors of febrile neutropenia in any cycle
Multivariable regression identified the following factors
to be significantly associated with a higher occurrence
of FN: lower platelet count and lower haemoglobin at
Table 2 List of included single nucleotide polymorphisms (SNPs), and their frequencies (percentages)
Genotype
Gene n GG GA AA CC CA
n (%) n (%) n (%) n (%) n (%)
ABCC2/MRP2rs8187710 954 842 (88.3) 110 (11.5) 2 (0.2)
ABCG2/BRCPrs2231137 955 888 (93.0) 67 (7.0)
CYP2B6rs2279343 910 57 (6.2) 382 (42.0) 471 (51.8)
CYP2C8rs72558196 960 960 (100)
CYP2C9rs1057910 954 853 (89.4) 3 (0.3) 98 (10.3)
CYP2C19rs4244285 946 652 (68.9) 266 (28.1) 28 (3.0)
CYP2C19rs4986893 960 960 (100)
CYP3A4rs2740574 955 2 (0.2) 57 (6) 896 (93.8)
CYP3A4rs55785340 957 957 (100)
CYP3A5rs776746 959 834 (87.0) 118 (12.3) 7 (0.7)
DPYDrs1801159 960 47 (4.9) 267 (27.8) 646 (67.3)
DPYDrs3918290 949 945 (99.6) 4 (0.4)
DPYDrs1801160 957 853 (89.1) 96 (10.0) 8 (0.9)
GSTA1rs3957357 938 329 (35.1) 441 (47.0) 168 (17.9)
GSTP1rs1695 959 118 (12.3) 452 (47.1) 389 (40.6)
MRP1rs1883112 956 295 (30.9) 485 (50.7) 176 (18.4)
MRP1rs7853758 952 701 (73.6) 231 (24.3) 20 (2.1)
MTHFRrs1801131 951 446 (46.9) 92 (9.7) 413 (43.4)
UGT2B7rs12233719 949 949 (100)
UGT2B7rs7662029 955 210 (22.0) 473 (49.5) 272 (28.5)
XPD/ERCC2rs1799793 954 412 (43.2) 429 (45.0) 113 (11.8)
XRCC1rs25489 954 875 (91.7) 77 (8.1) 2 (0.2)
XRCC3rs861534 949 357 (37.6) 441 (46.5) 151 (15.9)
Gene n TT CC CT AA TA
n (%) n (%) n (%) n (%) n (%)
ABCC2/MRP2rs17222723 951 843 (88.6) 2 (0.2) 106 (11.2)
ABCC2/MRP2rs2804402 935 297 (31.8) 185 (19.8) 453 (48.4)
CYP2B6rs8192709 927 846 (91.3) 87 (8.7)
CYP2C8rs10509681 960 740 (77.1) 12 (1.2) 208 (21.7)
CYP2C9rs1799853 957 15 (1.6) 712 (74.4) 230 (24)
CYP3A4rs4986910 959 938 (97.8) 21 (2.2)
DPYDrs1801265 960 635 (66.1) 46 (4.8) 279 (29.1)
FGFR4rs351855 954 88 (9.2) 461 (48.3) 405 (42.5)
GSTP1rs1138272 952 6 (0.6) 778 (81.7) 168 (17.7)
MDRI/ABCB1rs1045642 914 265 (29.0) 208 (22.8) 441 (48.2)
MRP1rs13058338 949 482 (50.8) 67 (7.1) 400 (42.1)
MRP1rs246221 956 462 (48.3) 71 (7.4) 423 (44.3)
MRP1rs3743527 930 13 (1.4) 562 (60.4) 355 (38.2)
MRP1rs4673 954 115 (12.0) 406 (42.6) 433 (45.4)
MTHFRrs1801133 959 121 (12.6) 401 (41.8) 437 (45.6)
NQO1rs1800566 958 35 (3.6) 605 (63.2) 318 (33.2)
UGT2B7rs7439366 955 272 (28.5) 210 (22.0) 473 (49.5)
UGT2B7rs7668282 954 940 (98.5) 1 (0.1) 13 (1.4)
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Table 2 List of included single nucleotide polymorphisms (SNPs), and their frequencies (percentages) (Continued)
Gene n GG GT TT CC CG
n (%) n (%) n (%) n (%) n (%)
ALDH3A1rs2228100 934 67 (7.2) 554 (59.3) 313 (33.5)
CYP2B6rs3745274 954 535 (56.1) 365 (38.2) 54 (5.7)
GPX4rs757229 940 263 (28.0) 212 (22.5) 465 (49.5)
MRP1rs4148350 957 847 (88.5) 105 (11.0) 5 (0.5)
MRP1rs45511401 960 847 (88.2) 109 (11.4) 4 (0.4)
UGT2B7rs3924194 954 19 (2.0%) 712 (74.6) 223 (23.4)
XPD/ERCC2rs13181 951 116 (12.2) 449 (47.2) 386 (40.6)
Gene n GG GT TT GA TA
n (%) n (%) n (%) n (%) n (%)
MDRI/ABCB1rs2032582 948 283 (29.9) 445 (46.9) 185 (19.5) 23 (2.4) 12 (1.3)
TYMSrs11280056 918 AAGTTA442 (48.2) AAGTTA.DEL394 (42.9) DEL82 (8.9)
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and rs246221 in MRP1 and rs351855 in FGFR4 (fibroblast
growth factor receptor 4) (Table 4). Homozygous carriers
of the rs4148350 T-allele had a higher risk of FN than car-
riers of the homozygous or heterozygous G-allele (FN risk
of 80% versus 15% or 25%). For rs246221, homozygous
carriers of the T-allele variant had a lower risk of FN than
carriers with at least one C-allele (FN risk of 13% versus
20% or 24%). Patients with the TT genotype of rs351855
were protected against FN compared to patients carrying
at least one C-allele (FN risk of 10% versus 19% or 16%).
The area under the ROC curve was 0.661 (CI 0.629-
0.691), as shown in Figure 1a: a value of 1 would denote
perfect discrimination and 0.5 discrimination no better
than chance. Overall, 864 of 910 patients (84.0%) were
correctly classified by the logistic regression model at a
predicted probability cut-off of 0.5; six out of 150 having
FN and 758 out of 760 not having FN. Sensitivity was
very low (4.0%) compared to specificity (99.7%). NPV
and PPV were similar; the proportion of patients cor-
rectly identified not to have FN was 84.0% and the pro-
portion of patients correctly identified to have FN was
75.0%. When the optimal cut-off of the model was used
(i.e., predicted probability of 0.1609, where sensitivity
and specificity were almost identical at 61.3%), the
model correctly classified 61.2% of the patients and PPV
and NPV were 23.8% and 88.9%, respectively. Internal
validity of the FN in any cycle model was satisfactory;
the 95% CIs of the bootstrap resampling were similar to
the 95% CIs calculated by the multivariable logistic re-
gression model.Risk factors of febrile neutropenia in cycle 1
Lower platelet count, haemoglobin at baseline, and lower
patient height were significantly associated with a higherrisk of FN in cycle 1 (Table 4). The SNP found to be sig-
nificantly associated with FN in cycle 1 was rs4148350
in MRP1. For rs4148350, homozygous carriers of the T-
allele had a higher risk of FN in cycle 1 than carriers of
the homozygous or heterozygous G-allele (FN risk of
40% versus 10% or 18%). We found a statistically signifi-
cant interaction between haemoglobin and height that
increased the protective effect of higher haemoglobin
and increased height but did not affect the other main
effects of the model.
The area under the ROC curve was 0.664 (CI 0.633-
0.694), as presented in Figure 1b. At a probability cut-off
of 0.5, one out of 98 patients was correctly classified
having FN in cycle 1 and all 839 patients without FN in
cycle 1 were correctly classified not having FN (overall,
89.7% correct classifications). Sensitivity was very low
(1.0%); specificity was 100%, PPV was 100%, and NPV
was 89.6%. At the optimal probability cut-off for the
model (0.1041), 61.5% of the patients were correctly
classified, sensitivity and specificity were 61%, PPV was
15.7%, and NPV was 93.1%. The 95% CIs of the boot-
strap resampling were similar to the 95% CIs calculated
by the multivariable logistic regression model, which
supports the internal validity of the FN in the first cycle
model.Discussion
In this population of early breast cancer patients seen in
routine clinical practice at a tertiary referral centre, we
identified a set of genetic factors, in addition to patient-
related and chemotherapy-related factors, that predict
occurrence of FN in any cycle or the first cycle of
chemotherapy. Significant predictors of a higher risk of
FN in any cycle and in cycle one were: lower baseline
platelet count, lower baseline haemoglobin, and carriers
Table 3 Candidate predictors from univariable analysis
FN in any cycle FN in cycle 1
Variable OR (95% CI) p-value OR (95% CI) p-value
Platelets (109/L, per 10 units change) 0.96 (0.93; 0.98) 0.002 0.95 (0.92; 0.99) 0.005
ANC (109/L) 0.87 (0.77; 0.98) 0.023 0.86 (0.74; 1.00) 0.046
ALT (U/L, per 10 units change) 1.12 (1.02; 1.23) 0.024 - -
WBC (109/L) 0.90 (0.83; 0.99) 0.032 0.88 (0.79; 0.99) 0.028
Height (cm) - - 1.03 (1.00; 1.07) 0.043
Haemoglobin (g/dl) 0.87 (0.73; 1.02) 0.094 0.80 (0.66; 0.98) 0.030
Planned cycles FEC (6 vs. 3 cycles) 1.09 (0.98; 1.22) 0.129 - -
ASTa (U/L, per 10 units change) 1.09 (0.95; 1.24) 0.210 - -
BSA (m2) - - 2.44 (0.59; 10.03) 0.217
Creatinin (mg/dl) 2.04 (0.66; 6.33) 0.219 - -
Planned dose of epirubicin (100 mg/m2) - - 1.01 (0.99; 1.02) 0.217
MRP1rs4148350 0.000 0.004
- GT vs. GG 1.82 (1.12; 2.94) 0.015 2.09 (1.21; 3.61) 0.008
- TT vs. GG 22.06 (2.45; 198.96) 0.006 6.30 (1.04; 38.28) 0.045
MRP1rs45511401b 0.000 0.004
- GT vs. GG 1.80 (1.12; 2.89) 0.015 1.82 (1.05; 3.17) 0.034
- TT vs. GG 16.40 (1.69; 158.84) 0.016 9.20 (1.28; 66.20) 0.027
MRP1rs246221 0.004 0.039
- TT vs. CC 0.47 (0.25; 0.86) 0.014 0.49 (0.24; 1.00) 0.053
- TC vs. CC 0.80 (0.44; 1.45) 0.459 0.80 (0.40; 1.61) 0.530
FGFR4rs351855 0.098 - -
- CT vs. CC 1.25 (0.88; 1.77) 0.216
- TT vs. CC 0.60 (0.29; 1.24) 0.166
CYP3A4rs4986910 0.171 - -
- TC vs. TT 0.24 (0.03; 1.84)
XRCC3rs861534 0.130 0.044
- GG vs. AA 1.25 (0.76; 2.07) 0.381 1.73 (0.91; 3.29) 0.095
- GA vs. AA 0.86 (0.52; 1.42) 0.544 1.03 (0.53; 1.99) 0.930
TYMSrs11280056 0.114 - -
- AAGTTA.DEL vs. AAGTTA 0.88 (0.60; 1.27) 0.486
- DEL vs. AAGTTA 1.60 (0.91; 2.82) 0.100
GSTP1rs1695 0.228 - -
- AG vs. AA 0.75 (0.53; 1.08) 0.124
- GG vs. AA 0.70 (0.40; 1.25) 0.231
GSTA1rs3957357 - - 0.163
- GG vs. AA 0.95 (0.49; 1.83) 0.875
- GA vs. AA 1.45 (0.80; 2.65) 0.223
ALDH3A1rs2228100 - - 0.188
- GG vs. CC 1.86 (0.92; 3.76) 0.086
- GC vs. CC 1.27 (0.81; 1.98) 0.297
MRP1rs1883112 - - 0.187
- AG vs. AA 0.87 (0.52; 1.46) 0.594
- GG vs. AA 0.59 (0.32; 1.08) 0.087
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Table 3 Candidate predictors from univariable analysis (Continued)
UGT2B7rs7439366 - - 0.204
- TT vs. CC 1.08 (0.57; 2.04) 0.813
- TC vs. CC 1.52 (0.87; 2.65) 0.139
UGT2B7rs7662029 - - 0.204
- GG vs. AA 0.93 (0.49; 1.75) 0.813
- GA vs. AA 1.41 (0.86; 2.31) 0.174
ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; CI, confidence
interval; FEC, fluorouracil, epirubicin and cyclophosphamide; FN, febrile neutropenia; WBC, white blood cell count.
Odds ratios and 95% confidence intervals are reported per 1 unit change if not otherwise indicated.
aHighly correlated with alanine aminotransferase (Pearson’s correlation coefficient 0.76) and not included in multivariable analysis.
bHighly correlated with MRP1rs4148350 (Spearman correlation coefficient 0.81) and not included in multivariable analysis.
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http://www.biomedcentral.com/1471-2407/14/201of the rs4148350 T-allele variant in MRP1, especially
homozygous T-allele carriers. Patients with lower ALT and
homozygous carriers of the rs246221 variant T-allele in
MRP1 and rs351855 variant T-allele in FGFR4 had a lower
risk of FN occurrence. Although the predictive ability of
the models was improved by including genetic factors, the
overall predictive ability remained poor. Genetic effects
were stable and FN occurrence was very high in patients
with specific SNP allele variants.
The observed effects of lower baseline platelet count
and haemoglobin are consistent with previous reports.
Baseline platelet count has been shown to differ between
cancer patients with mild and severe haematologicalTable 4 Logistic regression models for febrile neutropenia oc
Determinant FN in any cycle (n = 910)
Odds ratio (95% CI)
Platelets (109/L, per 10 units change) 0.952 (0.923; 0.981)
Hb (g/dl) 0.812 (0.673; 0.978)
Height (cm) -
Interaction (height and Hb)a -
ALT (U/L, per 10 unit change) 1.173 (1.056; 1.303)
MRP1rs4148350
- GTb vs. GG 1.494 (0.890; 2.507)
- TTc vs. GG 17.13 (1.72; 170.90)
MRP1rs246221
- TTd vs. CC 0.501 (0.259; 0.969)
- TC vs. CC 0.805 (0.423; 1.533)
FGFR4rs351855
-CT vs. CC 1.253 (0.862; 1.821)
-TTe vs. CC 0.505 (0.230; 1.113)
ALT, alanine aminotransferase; CI, Confidence interval; FN, febrile neutropenia; HB, h
Odds ratios and 95% confidence intervals are reported per 1 unit change if not oth
aDid not affect the odds ratio of the other main effects of the regression model.
b105/957 (11.0%) patients are carriers of the GT genotype and 19 (18.1%) out of tho
c5/957 (0.5%) patients are homozygous carriers of the T-allele and 4 (80%) out of th
(40%) had febrile neutropenia in cycle 1.
d462/956 (48.3%) patients are homozygous carriers of the T-allele and 59 (12.8%) ou
e88/954 (9.2%) patients are homozygous carriers ot the T-allele and 9 (10.2%) out otoxicity [16], and low haemoglobin has been mentioned as
possible risk factor for FN [27] and survival [28]. In the
model of FN occurrence in any cycle, higher baseline ALT
was significantly associated with FN but not baseline bili-
rubin [9,29]. Both measures are indicators of liver function
and since the liver detoxifies drugs like epirubicin [30],
impaired liver function may be an important risk factor
for FN occurrence in patients receiving chemotherapy
with epirubicin. A predictive role for WBC or ANC in
CIN and FN occurrence in cancer patients receiving
chemotherapy has been described in other studies [9-12],
but could not be confirmed in our models. Most SNPs
previously associated with FN occurrence [18] andcurrence in any cycle and the first cycle of chemotherapy
FN in cycle 1 (n = 937)
p-value Odds ratio (95% CI) p-value
0.001 0.951 (0.917; 0.985) 0.006
0.029 0.001 (<0.001; 0.194) 0.009
- 0.617 (0.414; 0.919) 0.018
- 1.040 (1.008; 1.072) 0.012
0.003 - -
0.019 0.006
0.129 2.149 (1.226; 3.768) 0.008
0.016 6.696 (1.039; 43.167) 0.046
0.023 - -
0.040
0.510
0.062 - -
0.238
0.090
aemoglobin.
erwise indicated.
se 105 patients had febrile neutropenia in cycle 1 of chemotherapy.
ose 5 patients had febrile neutropenia in any cycle of chemotherapy and 2
t of those 462 patients had febrile neutropenia in any cycle of chemotherapy.
f those 88 patients had febrile neutropenia in any cycle of chemotherapy.
Figure 1 Receiver operating characteristic curve for febrile
neutropenia occurrence in a) any cycle and b) cycle 1 of
chemotherapy. ROC, receiver operating characteristic. *bysecting line
indicates a predictiove ability that is no better than chance (ROC = 0.5).
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toxicity [31-33] were confirmed in the multivariable ana-
lysis. The SNP rs45511401 was not included in the
multivariable regression model as it was highly corre-
lated with rs4148350, and the latter variant explained
the model variability slightly better. There were no cor-
relations between SNPs included in the final model and
patient- or chemotherapy-related factors.
International guidelines [5,7,8] and the literature [9,12]
report age, planned dose intensity, and planned number
of chemotherapy cycles to be important risk factors for
CIN and FN during chemotherapy. These risk factors
could not be confirmed in our models. Patient-specific
approaches to clinical management were not recorded in
detail in this study and might therefore have masked the
effect of age on FN occurrence. In addition, the exact
cycle of FN occurrence was not available after the first
cycle. Factors previously reported to protect against CIN
and FN in any cycle of chemotherapy, such as dose re-
ductions, dose delays, or growth factor use before an
event occurred, could not be investigated since the details,
reasons, and timing information were not available andonly 15 out of 994 patients received primary prophylaxis
with GCSF, mainly due to reimbursement criteria.
The apparent predictive ability, i.e., the predictive abil-
ity assessed in the ‘training’ dataset used to develop the
models, was lower than in previously published models
of CIN or FN occurrence in other cancers [9,11,34]. In
these models, sensitivity and specificity at the optimal
predicted probability cut-off was about 70% or higher,
but in this study it remained below 70%. As commonly
seen in models of FN occurrence, the NPV (≥ 90%) was
much higher than the PPV because FN incidence is
often around 20%; this implies an NPV of around 80%
for simply assuming that FN does not occur in any pa-
tient. The areas under the ROC curves were relatively
low but significantly higher than 0.5, the value indicating
no predictive ability. In other words, the models allowed
partial discrimination of patients at low or high risk of
FN. Including genetic risk factors improved the models
but absolute predictive ability remained rather low. The
effects of the SNPs were stable and FN occurrence was
very high in patients with specific, sometimes rare, SNP
allele variants. In terms of clinical implications, genetic
testing might help to identify a small proportion of pa-
tients at very high risk of FN who can be targeted with
prophylactic measures. For the majority of patients, the
current models do not reliably identify patients that will
develop FN, but they do delineate patients who are un-
likely to develop FN. This is clinically relevant since pa-
tients at low risk of FN probably do not need primary
GCSF prophylaxis or nadir assessment, while the high-
risk group is unpredictable and might need more exten-
sive preventive measures or follow-up.
The performance of any model tends to be highest in
the training dataset. The results obtained with bootstrap
resampling supported the internal validity of the FN in
any cycle and the FN in first cycle models. The predictive
ability of the models has yet to be tested in an entirely in-
dependent population, where model performance is usu-
ally lower. Before risk models are put to clinical use, true
external validation is essential [35,36]. Another limitation
of this study is the retrospective design; no detailed infor-
mation was available on patient management in clinical
practice, which is known to influence the risk of FN oc-
currence, and the reasons and timing of dose reductions
and dose delays were not available. FN occurrence was
not assessed according to chemotherapy cycle beyond the
first cycle. GCSF was only administered to 15 patients be-
fore an event occurred due to stringent reimbursement
criteria. Hence, the impact of GCSF on FN occurrence
was difficult to assess.
To the best of our knowledge, this is the first study of
risk of FN in the first and any cycle of chemotherapy in
patients with early breast cancer that combined a set of
patient- and chemotherapy-related factors with a large
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firm our findings, which should ideally be prospectively
designed, sufficiently powered, and measure all possible
predictors of FN occurrence reported in the literature. Ap-
proaches to clinical management that are measurable and
known to influence the risk of FN occurrence, such as
dose modifications or growth factor use before an FN
event occurred, should be included. Information on SNPs
should be available for as many patients as possible and
the frequencies of possible genotypes of one SNP should
be similar. Validated genetic factors have the potential to
become reliable predictors of FN occurrence. The specific
SNPs that were assessed in this study are independent
from clinical decision-making and therefore less likely to
be confounded by clinical practice.
Conclusions
We have identified a set of chemotherapy-related, patient-
related, and genetic risk factors that predict occurrence of
FN in the first and any cycle of chemotherapy in a large
cohort of early breast cancer patients. Genetic effects in
the models improved the predictive ability, but the overall
predictive ability of the models remained poor. FN occur-
rence was very high in patients with specific SNP allele
variants. Up-front genetic testing might be helpful to iden-
tify a limited group of very high-risk patients. Further in-
dependent validation is required to develop risk models
that include genetic predictors of FN occurrence and can
be used to personalise care.
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